Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-FOX in Untreated Gastric/GEJ Adenocarcinoma
NCT00526110Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2004
- Primary completion
- Jun 2015
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Maximum Tolerated Dose at 28 days and Progression Free Survival at 30 months. Started Aug 2004; status: completed.
02
Drugs
oxaliplatin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT00526110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00526110.